In early-stage HER2+ BC tumors, PD-L1 immunoreactivity is documented in around 30% of cases, whereas a significant decrease in PD-L1 expression (9–10%) is observed in metastatic tumors [54,55]. The gene discussed is ERBB2; the disease is breast cancer.